DOCSLIB.ORG

Differentiation of Hemorrhage from Iodinated Contrast in Different Intracranial Compartments Using Dual-Energy Head CT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differentiation of Hemorrhage from Iodinated Contrast in Different Intracranial Compartments Using Dual-Energy Head CT Published January 19, 2012 as 10.3174/ajnr.A2909 Differentiation of Hemorrhage from Iodinated Contrast in Different Intracranial Compartments ORIGINAL RESEARCH Using Dual-Energy Head CT C.M. Phan BACKGROUND AND PURPOSE: Identification of ICH, particularly after ischemic stroke therapy, is A.J. Yoo important for guiding subsequent antithrombotic management and is often confounded by contrast staining or extravasations within intracerebral or extra-axial compartments. This study evaluates the J.A. Hirsch accuracy of DECT in distinguishing ICH from iodinated contrast in patients who received contrast via R.G. Nogueira IA or IV delivery. R. Gupta MATERIALS AND METHODS: Forty patients who had received IA or IV contrast were evaluated using a DECT scanner at 80kV and 140kV to distinguish hyperdensities secondary to contrast staining or extravasation from those representing ICH. A 3-material decomposition algorithm was used to obtain virtual noncontrast images and iodine overlay images. Sensitivity, specificity, and accuracy of DECT in prospectively distinguishing intracranial contrast from hemorrhage within parenchymal, subarachnoid, extra-axial, intraventricular, and intra-arterial compartments were computed using routine clinical follow-up imaging as the standard of reference. RESULTS: A total of 148 foci of intracranial hyperattenuation were identified. Of these, 142 were correctly classified for the presence of hemorrhage by DECT. The sensitivity, specificity, and accuracy for identifying hemorrhage, depending on the compartment being considered, were 100%, 84.4%– 100%, and 87.2%–100%, respectively. The only instances where DECT failed to correctly identify the source of hyperattenuation was in the presence of diffuse parenchymal calcification (n ϭ 5) and a metallic streak artifact (n ϭ 1). CONCLUSION: After IA and/or IV contrast administration, DECT can accurately differentiate all types of ICH from iodinated contrast without employing any additional radiation. ABBREVIATIONS: BP ϭ brain parenchyma; CNR ϭ contrast-to-noise ratio; DECT ϭ dual-energy CT; HEAD & NECK HU ϭ Hounsfield unit; IA ϭ intra-arterial; IAT ϭ intra-arterial therapy; ICH ϭ intracranial hemorrhage; SE ϭ single energy; VNCϭ virtual noncontrast taining of brain parenchyma and blood vessels is a well- or IV contrast administration, it can be difficult to differenti- 1 Srecognized phenomenon of IA contrast administration. ate a hyperattenuation resulting from iodinated contrast ver- ORIGINAL RESEARCH Furthermore, extravasation of contrast into the subarachnoid sus that arising from intracranial hemorrhage.2 This differen- space is fairly commonly seen following intra-arterial stroke tiation is especially critical in the setting of acute stroke or therapy with mechanical devices. These phenomena can also trauma, when antithrombotic therapy is being considered. be seen with IV contrast administration. For example, both The current standard of care for such discrimination is repeat intratumoral hemorrhage and contrast enhancement are follow-up imaging1: Contrast staining generally washes out common. Hemorrhagic transformation and gyriform en- within 24–48 hours, while hemorrhage persists for days to hancement of subacute stroke are well described, and distin- weeks. guishing them is clinically important. When contrast is ad- Early results have shown that DECT can distinguish hem- ministered in the setting of intracranial hemorrhage, petechial orrhage from iodinated contrast.3-5 This discrimination is extravasation of contrast in this hemorrhagic bed is a well- based on the differences between the photoelectric and Comp- recognized phenomenon and has been dubbed the “spot ton scattering components underlying the x-ray attenuation sign.” of hemorrhage and iodine. Because both phenomena are de- On a routine noncontrast head CT scan performed after IA pendent on the x-ray photon energy, one can discriminate the pixel attenuation arising from these 2 effects by scanning at 2 Received July 10, 2011; accepted after revision August 29. different energy levels, such as 80kV and 140kV. Assuming From the Department of Radiology (C.M.P., A.J.Y., J.A.H., R.G.), Massachusetts General Hospital, Boston, Massachusetts; Departments of Neurology, Neurosurgery, and Radiology that there can only be hemorrhage and/or iodine (in addition (R.G.N.), Emory University School of Medicine, Marcus Stroke & Neuroscience Center, to water and tissue), this information can be used to determine Grady Memorial Hospital, Atlanta, Georgia; Department of Neurology (R.G.N.), Massachu- the amount of each material present in each voxel. setts General Hospital, Harvard Medical School, Wang Ambulatory Care Center, Boston, Massachusetts. In this research, we considered a mixed cohort after both IA C.M.P. and A.J.Y. contributed equally to this article. and IV contrast administration. The overall goal was to estab- lish the general hypothesis that DECT is useful in all settings Please address correspondence to Catherine M. Phan, Department of Radiology, Massa- chusetts General Hospital, 55 Fruit St, Neuroradiology GRB-273A, Boston, MA 02114; where one has to distinguish between ICH and iodine from e-mail: [email protected] prior contrast administration, irrespective of how the contrast Indicates article with supplemental on-line tables. was administered. The sensitivity, specificity, and accuracy of http://dx.doi.org/10.3174/ajnr.A2909 DECT in differentiating hemorrhage from iodinated contrast AJNR Am J Neuroradiol ●:● ͉ ● 2012 ͉ www.ajnr.org 1 Copyright 2012 by American Society of Neuroradiology. were assessed for the intraparenchymal, subarachnoid, extra- settings split the overall dose nearly equally between the 2 imaging axial, intraventricular, and intra-arterial compartments. chains. The total effective dose was similar to that in a conventional head CT (approximately 3 mSv). The average CT dose index-volume Materials and Methods for a dual-energy head scan was 66 mGy, which is quite similar to that for a single-energy conventional head CT. It is also well within the Patient Selection American College of Radiology guidelines of 80 mGy. The patients were prospectively screened and retrospectively ana- The projection data acquired at 80 and 140 kV were reconstructed lyzed. The determination of which patients were routed to the DECT separately at 4.0-mm section thickness using an H30 kernel (medium scan was based on the following criteria: 1) all patients who received smooth), generating 3 sets of images: an 80-kV image, a 140-kV im- IAT after an acute stroke, and 2) patients who received IV contrast for age, and an SE image. The SE image set, which is a weighted sum of the any reason (eg, carotid stent placement, tumor evaluation, or 80-kV and 140-kV images, simulates an equivalent 120-kV image; it trauma), where a question of hemorrhage versus contrast was raised has a higher signal intensity–to-noise ratio than the constituent 80- by an SE energy scan. and 140-kV image sets. This study was approved by the local institutional review board Dual-energy postprocessing was performed using dedicated soft- (IRB Protocol #2008P002351). The requirement for informed con- ware (Syngo Dual Energy Brain Hemorrhage, Siemens): Images were sent for the retrospective analysis was waived by the IRB. From Octo- reconstructed at 1.5-mm section thickness, with 0.7-mm increments ber 2008 to May 2010, 40 patients (mean age 64.9 years; range 28–94) (D30s kernel). The analysis of low- and high-energy images7,8 was were referred for a DECT scan and were included in the analysis. performed using a 3-material decomposition algorithm based on There were 27 men (mean age 63.1 years; range 28–94) and 13 women brain parenchyma, hemorrhage, and iodine, producing a VNC and an (mean age 68.7 years; range 43–84). The study cohort included 20 iodine-only overlay image. DECT allows one to split every voxel in the acute stroke patients, of whom 18 underwent IAT; 15 patients evalu- acquired (80 kV, 140 kV) image pair along any 2 preselected base ated for carotid stenosis; 3 patients evaluated for trauma; and 2 pa- materials. In this application, the 2 base materials were BP and ICH. If tients evaluated for tumor assessment. At our institution, all stroke each voxel only consisted of these 2 materials, its measured attenua- patients who undergo conventional angiography for intra-arterial tion would be a linear combination of the attenuation values of BP embolectomy or thrombolysis are evaluated by using a postprocedure and ICH, both at 80 kVp and 140 kVp. To the extent the measured noncontrast CT for any complications. Therefore, this cohort consti- value of a voxel does not conform to a mixture of the 2 base materials, tuted the largest subpopulation of patients scanned by DECT. All IAT the difference can be attributed to a third preselected material. In the patients were scanned within 30 minutes of the end of the interven- current application, the third material chosen was iodine. The offset tional procedure. from the linear combination of ICH and BP represents the amount of It should be noted that our cohort of patients includes 15 cases iodinated contrast present in a voxel. The iodine-only images display with suspected carotid stenosis and old strokes. These patients under- this offset, and the VNC images display a combination of BP and ICH went a DECT angiogram that included a dual-energy head CT. These values. It should be noted that DECT is limited to 3-material decom- cases do not contribute to the hyperattenuated lesions that
Load more

Recommended publications
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • "Fullness" of the Pancreas on CT. Usually Benign, but EUS Plus/Minus FNA Is Warranted to Identify Malignancy
    JOP. J Pancreas (Online) 2009 Jan 8; 10(1):37-42. ORIGINAL ARTICLE Focal or Diffuse "Fullness" of the Pancreas on CT. Usually Benign, but EUS Plus/Minus FNA Is Warranted to Identify Malignancy John David Horwhat1, Henning Gerke2, Ruben Daniel Acosta1, Darren A Pavey3, Paul S Jowell3 1Gastroenterology Service, Department of Medicine, Walter Reed Army Medical Center. Washington, DC, USA. 2Division of Gastroenterology, Department of Medicine, University of Iowa Hospitals and Clinics. Iowa City, IA, USA. 3Division of Gastroenterology, Department of Medicine, Duke University Health System. Durham, NC, USA ABSTRACT Context The role of EUS to evaluate subtle radiographic abnormalities of the pancreas is not well defined. Objective To assess the yield of EUS±FNA for focal or diffuse pancreatic enlargement/fullness seen on abdominal CT scan in the absence of discrete mass lesions. Design Retrospective database review. Setting Tertiary referral center. Patients and interventions Six hundred and 91 pancreatic EUS exams were reviewed. Sixty-nine met inclusion criteria of having been performed for focal enlargement or fullness of the pancreas. Known chronic pancreatitis, pancreatic calcifications, acute pancreatitis, discrete mass on imaging, pancreatic duct dilation (greater than 4 mm) and obstructive jaundice were excluded. Main outcome measurement Rate of malignancy found by EUS±FNA. Results FNA was performed in 19/69 (27.5%) with 4 new diagnoses of pancreatic adenocarcinoma, one metastatic renal cell carcinoma, one metastatic colon cancer, one chronic pancreatitis and 12 benign results. Eight patients had discrete mass lesions on EUS; two were cystic. All malignant diagnoses had a discrete solid mass on EUS. Conclusions Pancreatic enlargement/fullness is often a benign finding related to anatomic variation, but was related to malignancy in 8.7% of our patients (6/69).
    [Show full text]
  • Review Article Contrast Media Viscosity Versus Osmolality in Kidney Injury: Lessons from Animal Studies
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 358136, 15 pages http://dx.doi.org/10.1155/2014/358136 Review Article Contrast Media Viscosity versus Osmolality in Kidney Injury: Lessons from Animal Studies Erdmann Seeliger, Diana C. Lenhard, and Pontus B. Persson Institute of Physiology and Center for Cardiovascular Research, Charite-University´ Medicine Berlin, Campus Mitte, Hessische Straße 3-4, 10115 Berlin, Germany Correspondence should be addressed to Erdmann Seeliger; [email protected] Received 18 October 2013; Accepted 29 December 2013; Published 23 February 2014 Academic Editor: Richard Solomon Copyright © 2014 Erdmann Seeliger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Iodinated contrast media (CM) can induce acute kidney injury (AKI). CM share common iodine-related cytotoxic features but differ considerably with regard to osmolality and viscosity. Meta-analyses of clinical trials generally failed to reveal renal safety differences of modern CM with regard to these physicochemical properties. While most trials’ reliance on serum creatinine as outcome measure contributes to this lack of clinical evidence, it largely relies on the nature of prospective clinical trials: effective prophylaxis by ample hydration must be employed. In everyday life, patients are often not well hydrated; here we lack clinical data. However, preclinical studies that directly measured glomerular filtration rate, intrarenal perfusion and oxygenation, and various markers of AKI have shown that the viscosity of CM is of vast importance. In the renal tubules, CM become enriched, as water is reabsorbed, but CM are not.
    [Show full text]
  • When Is the Use of Contrast Media in Chest CT Indicated? Bruno Hochhegger1,2,3, Robson Rottenfusser4,5, Edson Marchiori6
    J Bras Pneumol. 2017;43(5):400-400 http://dx.doi.org/10.1590/S1806-37562017000000179 LETTER TO THE EDITOR When is the use of contrast media in chest CT indicated? Bruno Hochhegger1,2,3, Robson Rottenfusser4,5, Edson Marchiori6 TO THE EDITOR: nodule, small or large airway disease, and lung cancer screening, do not require the use of any contrast media. It is undeniable that CT plays an important role in the diagnosis and treatment of various clinical conditions However, for the assessment of vascular disease, CT involving the chest wall, mediastinum, pleura, pulmonary requires the use of an i.v. contrast agent to delineate the arteries, and lung parenchyma. The need for enhancement vessel lumen (e.g., aneurysm, dissection, and vascular using i.v. contrast media depends on the specific clinical tumor invasion). Pulmonary embolic disease is the third indication.(1-3) The most common contrast agents used most common cause of acute cardiovascular disease.(3,5) with CT imaging are iodinated. Intravenous iodinated Chest CT angiography is the most common way to assess contrast agents are used for opacification of vascular for pulmonary embolic disease because, in addition to structures. The major families of contrast agents are being accurate, fast, and widely available, it can assess ionic and nonionic. Contrast agents can be further alternate pathologies in cases of undifferentiated chest classified as high- or low-osmolality agents on the basis pain. Typically, the use of CT in order to investigate of the iodine concentration. Most centers use nonionic vascular disease or pleural pathology may include contrast agents (generally low-osmolality agents) for non-contrast-enhanced images to identify hemorrhage, i.v.
    [Show full text]
  • Coronary Artery Calcium Quantification in Contrast-Enhanced Computed Tomography Angiography
    Georgia State University ScholarWorks @ Georgia State University Computer Science Dissertations Department of Computer Science 12-18-2013 Coronary Artery Calcium Quantification in Contrast-enhanced Computed Tomography Angiography Abinashi Dhungel Georgia State University Follow this and additional works at: https://scholarworks.gsu.edu/cs_diss Recommended Citation Dhungel, Abinashi, "Coronary Artery Calcium Quantification in Contrast-enhanced Computed Tomography Angiography." Dissertation, Georgia State University, 2013. https://scholarworks.gsu.edu/cs_diss/80 This Dissertation is brought to you for free and open access by the Department of Computer Science at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Computer Science Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. CORONARY ARTERY CALCIUM QUANTIFICATION IN CONTRAST-ENHANCED COMPUTED TOMOGRAPHY ANGIOGRAPHY by ABINASHI DHUNGEL Under the Direction of Dr. Michael Weeks ABSTRACT Coronary arteries are the blood vessels supplying oxygen-rich blood to the heart muscles. Coronary artery calcium (CAC), which is the total amount of calcium deposited in these arteries, indicates the presence or the future risk of coronary artery diseases. Quantification of CAC is done by using computed tomography (CT) scan which uses attenuation of x- ray by different tissues in the body to generate three-dimensional images. Calcium can be easily spotted in the CT images because of its higher opacity to x-ray compared to that of the surrounding tissue. However, the arteries cannot be identified easily in the CT images. Therefore, a second scan is done after injecting a patient with an x-ray opaque dye known as contrast material which makes different chambers of the heart and the coronary arteries visible in the CT scan.
    [Show full text]
  • Iodinated Contrast Media and Their Adverse Reactions*
    Iodinated Contrast Media and Their Adverse Reactions* Jagdish Singh and Aditya Daftary Teleradiology Solutions, Bangalore, India acteristics, including their chemical structure, osmolality, Cross-use of technology between nuclear medicine and radiol- iodine content, and ionization in solution (2,3). ogy technologists is expanding. The growth of PET/CT and the The parent molecule from which the contrast agents are increasing use of intravenous contrast agents during these pro- derived is benzene. This is a toxic water-insoluble liquid. cedures bring the nuclear medicine technologist into direct con- The carbon atoms on a benzene ring are numbered clock- tact with these agents and their associated complications. A basic understanding of the occurrence, risk factors, clinical fea- wise from 1 to 6. Benzoic acid is produced by introducing tures, and management of these procedures is of increasing an acid group at position 1 on the benzene ring. This acid importance to the nuclear medicine technologist. After reading group permits the formation of salts or amides, which this article, the technologist will be able to list the factors that influence water solubility. 2,4,6-triiodobenzoic acid is ob- increase the risk of contrast reactions; understand ways to min- tained by introducing iodine atoms at positions 2, 4, and 6 imize the occurrence of contrast reactions; and develop a plan to on the ring. Iodine is the element used in contrast media identify, treat, and manage the reactions effectively. as it possesses 3 important properties essential for the Key Words: iodinated contrast media; contrast reactions production of contrast media: high-contrast density, firm J Nucl Med Technol 2008; 36:69–74 binding to the benzene molecule, and low toxicity.
    [Show full text]
  • Iodinated Contrast Media Guideline
    IODINATED CONTRAST MEDIA GUIDELINE FACULTY OF CLINICAL RADIOLOGY THE ROYAL AUSTRALIAN AND NEW ZEALAND COLLEGE OF RADIOLOGISTS® Name of document and version: Iodinated Contrast Media Guideline, V2.3 Approved by: Faculty of Clinical Radiology Date of approval: March 2018 Suggested Citation: The Royal Australian and New Zealand College of Radiologists. Iodinated Contrast Media Guideline. Sydney: RANZCR; 2018. ABN 37 000 029 863 Copyright for this publication rests with The Royal Australian and New Zealand College of Radiologists ® The Royal Australian and New Zealand College of Radiologists Level 9, 51 Druitt Street Sydney NSW 2000 Australia Email: [email protected] Website: www.ranzcr.edu.au Telephone: +61 2 9268 9777 Disclaimer: The information provided in this document is of a general nature only and is not intended as a substitute for medical or legal advice. It is designed to support, not replace, the relationship that exists between a patient and his/her doctor. Document name Iodinated Contrast Media Guideline Description The Iodinated Contrast Media Guideline is intended to assist The Royal Australian and New Zealand College of Radiologists®, its staff, Fellows, members and other individuals involved in the administration of iodinated contrast media to patients undergoing medical imaging procedures. Created By Standards of Practice and Accreditation Committee Date Created 2011 Maintained By Faculty of Clinical Radiology, Policy and Advocacy Unit Version Number Modifications Made Date Modified 2011 Document published 2.0 Document updated and published April 2016 2.1 Grammatical error corrected in R31 February 2017 2.2 Nitroglycerin dosages corrected in R39 June 2017 2.3 Adrenaline dosage corrected in R56 March 2018 Iodinated Contrast Media Guideline, V2.3 © The Royal Australian and New Zealand College of Radiologists® March 2018 Page 2 of 39 TABLE OF CONTENTS 1.
    [Show full text]
  • (320 Mg I/Ml), Solution for Injection Meglumine Ioxaglate and Sodium Ioxaglate
    HEXABRIX 320 (320 mg I/mL), solution for injection Meglumine ioxaglate and sodium ioxaglate Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What HEXABRIX 320, solution for injection is and what it is used for 2. What you need to know before you use HEXABRIX 320, solution for injection 3. How to use HEXABRIX 320, solution for injection 4. Possible side effects 5. How to store HEXABRIX 320, solution for injection 6. Contents of the pack and other information 1. WHAT HEXABRIX 320 IS AND WHAT IT IS USED FOR HEXABRIX 320 is a contrast agent. It belongs to the group of contrast agents used for radiological examinations. HEXABRIX 320 is used to enhance the contrast of the images obtained during these examinations, in order to improve the visualisation and delineation of certain parts of the body, such as: Certain hollow organs (opacification of body cavities), The uterus and fallopian tubes (ducts connecting the uterus to the ovaries) in female patients (hysterosalpingography), Blood vessels (angiography), Joints (arthrography), Urinary system (urography). This medicine is for diagnostic use only. 2.
    [Show full text]
  • Contrast CT Take? CT a Contrast CT Will Usually Take 15-20 Minutes
    Contrast How long will the procedure Image of a Contrast CT take? CT A Contrast CT will usually take 15-20 minutes. Risks of Procedure Women should always inform their doctor and CT technologist if there is any possibility that they are pregnant. CT scanning is, in general, not recommended for pregnant women unless medically necessary because of potential risk to the baby. Nursing mothers should wait for 24 hours after contrast material injection before resuming breast-feeding. With Ioscan, be careful not to aspirate (contents entering the lungs) as it can cause serious breathing difficulties. An abdomen CT during the portal-venous The risk of serious allergic reaction to contrast phase following an injection of IV contrast. The materials that contain iodine is extremely low, image shows the liver, gallbladder, kidneys, the and radiology departments are well-equipped to large and small bowel, aorta, vertebrae and deal with them. other smaller structures. If you have any related previous images from another provider please bring them on the day. For more information contact: Radiology Radiology Department Disclaimer: Swan Hill District Health The information contained in this brochure is Swan Hill 3585 intended as a guide only. If patients require more Ph: (03) 5033 9287 specific information please contact your referring Doctor. Publication Date: February 2013 What is a Contrast CT? Preparation CT scans of internal organs, bones, soft tissue Women must inform the radiographer if there is If you are over 55 years of age, your doctor will and blood vessels reveal more details than any chance that they are pregnant or if they are give you a pathology slip to have a ‘U & E’ blood regular x-rays.
    [Show full text]
  • Delayed Cutaneous Reactions to Iodinated Contrast
    CASE REPORT Delayed Cutaneous Reactions to Iodinated Contrast Daniel R. Mazori, MD; Arielle R. Nagler, MD; Miriam Keltz Pomeranz, MD agents were used: intravenous iohexol and oral diatri- PRACTICE POINTS zoate meglumine–diatrizoate sodium. The eruption was • Delayed cutaneous reactions to iodinated contrast not preceded by fever, malaise, sore throat, rhinorrhea, (IC) are common, but patients frequently are mis- cough, arthralgia, headache, diarrhea, or new medication diagnosed and inadvertently readministered the or supplement use. The patient denied any history of drug offending agent. allergy or cutaneous eruptions. Her current medications, • The most common IC-induced delayed reactions are which she had been taking long-term, were aspirin, self-limited exanthematous eruptions that develop lisinopril, diltiazem, levothyroxine, esomeprazole, parox- within 1 week of exposure. etine, gabapentin,copy and diphenhydramine. • Risk factors for delayed reactions to IC include Physical examination was notable for erythema- atopy, contrast exposure during high pollen season, tous, blanchable, nontender macules coalescing into use of the agent iodixanol, a history of other cutane- patches on the trunk and bilateral arms (Figure). ous drug eruptions, elevated serum creatinine levels, There was slight erythema on the nasolabial folds and and treatment with recombinant interleukin 2. ears.not The mucosal surfaces and distal legs were clear. • Dermatologists can help prevent recurrent reactions The patient was afebrile. Her white blood cell count in patients who require repeated exposure to IC by was 12.5×109/L with 32.3% eosinophils (baseline: white recommending gadolinium-based contrast agents blood cell count, 14.8×109/L; 22% eosinophils)(reference and/or premedication. Dorange, 4.8–10.8×109/L; 1%–4% eosinophils).
    [Show full text]
  • OSMOVIST Iotrolan Injection
    PRODUCT MONOGRAPH ® OSMOVIST Iotrolan Injection ® OSMOVIST 240 Iotrolan Injection 240 mg I/mL ® OSMOVIST 300 Iotrolan Injection 300 mg I/mL Dimeric Non-ionic Radiographic Contrast Medium For Myelography Bayer Inc. Date of Preparation: 77 Belfield Road April 11, 2007 Toronto, Ontario M9W 1G6 Canada www.bayer.ca Submission Control No.: 113334 © 2007, Bayer Inc. PRODUCT MONOGRAPH OSMOVIST® Iotrolan injection ® OSMOVIST 240 Iotrolan injection 240 mg I/mL ® OSMOVIST 300 Iotrolan injection 300 mg I/mL THERAPEUTIC CLASSIFICATION A Dimeric Non-ionic Radiographic Contrast Medium For Myelography ACTION and CLINICAL PHARMACOLOGY OSMOVIST (iotrolan) is a dimeric, non-ionic, hexaiodinated radiocontrast medium. The contrast-giving substance, iotrolan, is a dimer of triiodinated isophthalic acid derivatives, in which the firmly bound iodine absorbs the X-rays. Solutions of OSMOVIST 240 mg I/mL and 300 mg I/mL are isotonic to plasma and cerebrospinal fluid at radiologically useful iodine levels. After intrathecal administration, iotrolan is absorbed from cerebrospinal fluid (CSF) into the blood stream. The mean half-life of the transfer of iotrolan from the spinal fluid to the blood plasma was found to be 5.7 ± 6.0 hours in adults. The highest concentration of iodine in plasma occurred 3.5 ± 3.1 hours after intrathecal administration. Plasma protein binding at a concentration of 1.2 mg I/mL is 2.4%. The mean elimination half- Page 2 life of iotrolan in the plasma is 13.6 ± 13.9 hours (median of 9 hours). Approximately 50- 80% of the administered dose is excreted unmetabolized by the kidneys within 24 hours after administration, and approximately 90% within 72 hours.
    [Show full text]